Edesa Biotech appoints Peter J. Weiler as CFO starting May 1, 2025, succeeding Stephen Lemieux. Weiler brings extensive experience from leadership roles at Exzell Pharma and Biosyent Inc., blending scientific…
Edesa Biotech has appointed Peter J. Weiler as its new Chief Financial Officer, effective May 1, 2025. Weiler brings extensive experience from leadership roles at Exzell Pharma, Biosyent Inc., and…
A strategic partnership between Wacker Biotech and RNAV8 Bio aims to revolutionize mRNA-based therapies. The collaboration focuses on optimizing untranslated regions (UTRs) in mRNA strands to enhance drug effectiveness. Improved…
A groundbreaking partnership between Wacker Biotech and RNAV8 Bio aims to revolutionize mRNA-based therapies in biopharma. This collaboration combines Wacker Biotech's manufacturing prowess with RNAV8 Bio's advanced mRNA engineering techniques.…
Neurona Therapeutics has secured $102 million to advance its innovative cell therapy for epilepsy into phase 3 testing. The therapy, NRTX-1001, targets drug-resistant mesial temporal lobe epilepsy using GABAergic interneurons…
Biotechnology is undergoing a revolution through the integration of AI and genomic editing tools like CRISPR, enabling personalized medicine. AI rapidly analyzes complex biological data, aiding in the development of…
The Brooklyn Park Black History Month Showcase featured dynamic performances and speeches, celebrating heritage and resilience. The Lions Drum and Dance troupe opened with powerful rhythms, echoing historical struggles and…
Legend Biotech Corporation is becoming a significant player in the healthcare sector amidst financial strain and challenges like inflation and labor shortages. The U.S. healthcare technology market is expected to…
Thermo Fisher Scientific will lay off 300 employees by March 30 across Cambridge and Plainville. The layoffs come despite a reported 5% revenue increase for the fourth quarter of 2024.…
Evaxion Biotech raised $10.8 million through a recent public offering of nearly 4 million ADSs. The offering includes warrants for investors to buy up to 50% more ADSs at $2.71…